MedTrace Logo

Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome

NCT05183178 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16000

Last updated 2022-03-17

No results posted yet for this study

Summary

This study proposes to conduct the switch from ticagrelor to prasugrel in an organized stepwise manner, to allow for the evaluation of the relative efficacy of prasugrel versus ticagrelor using a stepped-wedge cluster randomized trial design.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Prasugrel 10 mg p.o

Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.

DRUG

Ticagrelor 90 mg

Ticagrelor 90 mg twice daily p.o.

Sponsors & Collaborators

  • Region Skane

    collaborator OTHER

  • Region Halland

    collaborator OTHER

  • Region Gävleborg

    collaborator OTHER

  • Region Örebro County

    collaborator OTHER

  • Region Västerbotten

    collaborator OTHER_GOV

  • Jämtland County Council, Sweden

    collaborator OTHER_GOV

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Elmir Omerovic, MD, PhD · Sahlgrenska Universitetssjukhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2025-01-31
Completion
2025-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05183178 on ClinicalTrials.gov